Toggle Health Problems and D

Omega-3 reduced vitamin D3 inflammation for obese – RCT Jan 2013

Treatment with n-3 Polyunsaturated Fatty Acids Overcomes the Inverse Association of Vitamin D3

D Deficiency with Inflammation in Severely Obese Patients: A Randomized Controlled Trial
Bianca K. Itariu, Maximilian Zeyda, Lukas Leitner, Rodrig Marculescu, Thomas M. Stulnig thomas.stulnig at meduniwien.ac.at
Clinical Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, Christian Doppler Laboratory for Cardio-Metabolic Immunotherapy, Medical University of Vienna, Vienna, Austria

Obesity affects the vitamin D status in humans. Vitamin D and long-chain n-3 polyunsaturated fatty acids (PUFA) provide benefit for the prevention of fractures and cardiovascular events, respectively, and both are involved in controlling inflammatory and immune responses. However, published epidemiological data suggest a potential interference of n-3 PUFA supplementation with vitamin D status. Therefore, we aimed to investigate in a randomized controlled clinical trial whether treatment with long chain n-3 PUFA affects vitamin D status in severely obese patients and potential interrelations of vitamin D and PUFA treatment with inflammatory parameters. Fifty-four severely obese (BMI≥40 kg/m2) non-diabetic patients were treated for eight weeks with either 3.36 g/d EPA and DHA or the same amount of butter fat as control. Changes in serum 25-hydroxy-vitamin D [25(OH)D] concentrations, plasma fatty acid profiles and circulating inflammatory marker concentrations from baseline to end of treatment were assessed. At baseline 43/54 patients were vitamin D deficient (serum 25(OH)D concentration <50 nmol/l). Treatment with n-3 PUFA did not affect vitamin D status (P = 0.91). Serum 25(OH)D concentration correlated negatively with both IL-6 (P = 0.02) and hsCRP serum concentration (P = 0.03) at baseline. Strikingly, the negative correlations of 25(OH)D with IL-6 and hsCRP were lost after n-3 PUFA treatment. In conclusion, vitamin D status of severely obese patients remained unaffected by n-3 PUFA treatment. However, abrogation of the inverse association of 25(OH)D concentration with inflammatory markers indicated that n-3 PUFA treatment could compensate for some detrimental consequences of vitamin D deficiency.

Trial Registration: ClinicalTrials.gov NCT00760760

PDF is attached at the bottom of this page

See also VitaminDWiki

This page was renamed Nov 2018. There have actually been 7129 visitors to this page since it was originally made

Created by admin. Last Modification: Saturday November 3, 2018 15:14:20 GMT-0000 by admin. (Version 6)